<DOC>
	<DOCNO>NCT01905813</DOCNO>
	<brief_summary>The study conduct three part . Part 1 dose escalation phase determine maximum tolerate dose ( MTD ) INCB040093 , PI3Kδ inhibitor , tolerate , pharmacologically active dose ; Part 2 evaluate combination INCB040093 itacitinib ( INCB039110 ) , JAK1 inhibitor , determine MTD combination tolerate dose produce substantial pharmacologic inhibition target ; Part 3 evaluate choose dose INCB040093 alone combination itacitinib ( INCB039110 ) subject relapsed/refractory B-cell malignancy .</brief_summary>
	<brief_title>Study INCB040093 Subjects With Previously Treated B-Cell Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>• Aged 18 year old , lymphoid malignancy Bcell origin follow : Indolent / aggressive Bcell ( NHL ) Non Hodgkin 's Lymphoma : EXCLUDING : Burkitt lymphoma precursor Blymphoblastic leukemia/lymphoma INCLUDING : nonHodgkin 's Bcell malignancy CLL rare nonHodgkin 's Bcell subtypes Hairy Cell Leukemia , Waldenstrom macroglobulinemia , Mantle cell lymphoma , transform NHL histology , etc . Hodgkin 's lymphoma Life expectancy 12 week longer . Subject must receive ≥ 1 prior treatment regimen . The subject must candidate potentially curative therapy , include stem cell transplant . Received investigational study drug within 28 day 5 halflives ( whichever longer ) prior receive first dose study drug . Received approved anticancer medication within 21 day 5 halflives ( whichever longer ) prior receive first dose study drug ( 42 day nitrosoureas ) EXCEPT steroid ≤ 10 mg prednisone daily ( equivalent ) . Has unresolved toxicity ≥ Grade 2 previous anticancer therapy . Has history brain metastasis spinal cord compression , lymphoma involve central nervous system . Has Eastern Cooperative Oncology Group ( ECOG ) performance status ≥ 3 . Received allogeneic hematopoietic stem cell transplant within last 6 month , active graft versus host disease ( GVHD ) follow allogeneic transplant , currently receive immunosuppressive therapy follow allogeneic transplant . Received autologous hematopoietic stem cell transplant within last 3 month . Laboratory parameter within protocoldefined range . Current recent history ( &lt; 30 day prior screen and/or &lt; 45 day prior dose ) clinically meaningful bacterial , fungal , parasitic mycobacterial infection . Current clinically active viral infection . Known history infection human immunodeficiency virus ( HIV ) . History active hepatitis positive serology hepatitis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>